Overview
Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2017 at the end of the 10-year period of market exclusivity.
On 16 June 2005, orphan designation (EU/3/05/293) was granted by the European Commission to GlaxoSmithKline Research & Development Limited, United Kingdom, for nelarabine for the treatment of acute lymphoblastic leukaemia. The sponsorship was transferred to Glaxo Group Limited, United Kingdom, in August 2006.
The sponsorship was transferred toGlaxo Group Limited, United Kingdom, in August 2006 and subsequently to Novartis Europharm Limited, United Kingdom, in April 2015.
Nelarabine has been authorised in the EU as Atriance since 22 August 2007.
Key facts
Active substance |
nelarabine
|
Medicine name |
Atriance
|
Intended use |
Treatment of acute lymphoblastic leukaemia
|
Orphan designation status |
Expired
|
EU designation number |
EU/3/05/293
|
Date of designation |
16/06/2005
|
Sponsor |
Novartis Europharm Limited |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: